


Product Name : PLX-4545
Cat. No. : PC-24555
CAS No. : 2892065-45-9
Molecular Formula : C₂₈H₃₁N₃O₄
Molecular Weight : 473.57
Target : PROTAC
Solubility : 10 mM in DMSO



CAS: 2892065-45-9

Biological Activity

PLX-4545 (PLX4545) is a potent and selective, orally bioavailable **IKZF2 degrader**, that depletes IKZF2 and converts suppressive Tregs into effector-like T-cells leading to antitumor immunity. Oral administration of PLX-4545 resulted in dose dependent depletion of IKZF2 and single agent antitumor activity in vivo. PLX-4545 treatment preferentially converted tumor Tregs into effector-like T-cells through decreased CD25 expression and increased production of effector cytokines (IL2, IFN γ), resulting in increased infiltration of CD4/8 Teff cells into tumor tissue. Combination of PLX-4545 with anti-PD1 significantly increased the proliferation of Teff cells and inhibition of tumor growth in vivo.

References

Yujun Huang, et al. *Cancer Res* (2025) 85 (8_Supplement_1): 6380.

Chen Z, et al. *Nat Commun*. 2025 May 1;16(1):4095.

Caution: Product has not been fully validated for medical applications. Lab Use Only!

E-mail: tech@probechem.com